Recombinant expression and characterization of novel P450s from Actinosynnema mirum

The potential roles of carotenoids in enhancing phytoremediation of bisphenol A contaminated soil by promoting plant physiology and modulating rhizobacterial community of tobacco

The widespread occurrence of bisphenol A (BPA), a typical endocrine-disrupting compound, poses potential threat to ecosystem and public health. Carotenoids are essential natural pigments, playing important roles in photosynthesis and antioxidant defense of plants. This study aimed to verify the value of carotenoids in enhancing plant tolerance to BPA stress and improving phytoremediation efficiency of tobacco (Nicotiana tabacum L.), through exogenous application of β-carotene (a typical carotenoid) and endogenous upregulation of carotenoids by overexpression of β-carotene hydroxylase (chyb) gene in tobacco. The results demonstrated that exogenous applied β-carotene alleviated the toxic effects of BPA exposure (100 mg kg^-1) on wild-type (WT) tobacco plants after being cultivated for 40 d, reflecting by the increase of biomass (201.2%), chlorophyll content (27.5%) and the decrease of malondialdehyde (MDA) content (70.7%). Similar with the results of exogenous application of β-carotene, chyb gene overexpressing tobacco showed less phytotoxicity exposed to BPA, through enhancing photosynthetic efficiency (42.1%) and reducing reactive oxygen species (ROS) production (18%). Notably, about 94.8% BPA in contaminated soil was removed under the cultivation of transgenic tobacco for 40 d, however, only 82.7% was removed in that of WT tobacco. Moreover, transgenic tobacco is beneficial for the growth of plant roots, thus upregulating the abundance of bacteria contributing to BPA degradation or soil nutrient cycling (e.g., Proteobacteria, Acidobacteria, Actinobacteria, Sphingomonas and MND1), which might further help to enhance plant growth and improve BPA removal efficiency in soil. This study extended our understanding of the possible mechanisms of carotenoids-involved alleviation of BPA stress in tobacco, providing a novel strategy to improve phytoremediation efficiency of plants in BPA contaminated soil.

Opportunities for Accelerating Drug Discovery and Development by Using Engineered Drug-Metabolizing Enzymes

The study of drug metabolism is fundamental to drug discovery and development (DDD) since by mediating the clearance of most drugs, metabolic enzymes influence their bioavailability and duration of action. Biotransformation can also produce pharmacologically active or toxic products, which complicates the evaluation of the therapeutic benefit versus liability of potential drugs but also provides opportunities to explore the chemical space around a lead. The structures and relative abundance of metabolites are determined by the substrate and reaction specificity of biotransformation enzymes and their catalytic efficiency. Preclinical drug biotransformation studies are done to quantify in vitro intrinsic clearance to estimate likely in vivo pharmacokinetic parameters, to predict an appropriate dose, and to anticipate interindividual variability in response, including from drug-drug interactions. Such studies need to be done rapidly and cheaply, but native enzymes, especially in microsomes or hepatocytes, do not always produce the full complement of metabolites seen in extrahepatic tissues or preclinical test species. Furthermore, yields of metabolites are usually limiting. Engineered recombinant enzymes can make DDD more comprehensive and systematic. Additionally, as renewable, sustainable, and scalable resources, they can also be used for elegant chemoenzymatic, synthetic approaches to optimize or synthesize candidates as well as metabolites. Here, we will explore how these new tools can be used to enhance the speed and efficiency of DDD pipelines and provide a perspective on what will be possible in the future. The focus will be on cytochrome P450 enzymes to illustrate paradigms that can be extended in due course to other drug-metabolizing enzymes. SIGNIFICANCE STATEMENT: Protein engineering can generate enhanced versions of drug-metabolizing enzymes that are more stable, better suited to industrial conditions, and have altered catalytic activities, including catalyzing non-natural reactions on structurally complex lead candidates. When applied to drugs in development, libraries of engineered cytochrome P450 enzymes can accelerate the identification of active or toxic metabolites, help elucidate structure activity relationships, and, when combined with other synthetic approaches, provide access to novel structures by regio- and stereoselective functionalization of lead compounds.

Tobacco-associated with Methylophilus sp. FP-6 enhances phytoremediation of benzophenone-3 through regulating soil microbial community, increasing photosynthetic capacity and maintaining redox homeostasis of plant

Benzophenone-3 (BP-3) has attracted widespread attention due to its large accumulation in the environment and its potential toxicity effects to human. This study aimed to investigate the effects of the combined application of tobacco and Methylophilus sp. strain FP-6 with both plant growth promoting (PGP) traits and BP-3 degradation function on BP-3 remediation in soil. The results showed that about 79.18% of BP-3 was removed from the soil after 30 days of plant culture inoculated with the FP-6 strain, which was significantly higher than the plant-alone treatment. Simultaneously, inoculation with strain FP-6 significantly improved growth performance, biomass production, antioxidant levels, osmoregulation substance, photosynthetic capacity and chlorophyll accumulation in tobacco. Moreover, the application of FP-6 shifted the bacterial community, and enhanced the abundance of BP-3-degrading or soil nutrient cycling-affecting bacteria (e.g., Chloroflexi, Bryobacter, MND1 and Myxococcales), which might be valuable for the promotion of plant growth and degradation of BP-3 in the soil. The results from this study gave first insights into the enhancement of BP-3 removal efficiency from soil by phytoremediation assisted with bacteria possessing both PGP properties and BP-3 degradation function. The role of soil bacterial community in this remediation process was also discussed.

Recent Advances in Biocatalysis for Drug Synthesis

Biocatalysis is constantly providing novel options for the synthesis of active pharmaceutical ingredients (APIs). In addition to drug development and manufacturing, biocatalysis also plays a role in drug discovery and can support many active ingredient syntheses at an early stage to build up entire scaffolds in a targeted and preparative manner. Recent progress in recruiting new enzymes by genome mining and screening or adapting their substrate, as well as product scope, by protein engineering has made biocatalysts a competitive tool applied in academic and industrial spheres. This is especially true for the advances in the field of nonribosomal peptide synthesis and enzyme cascades that are expanding the capabilities for the discovery and synthesis of new bioactive compounds via biotransformation. Here we highlight some of the most recent developments to add to the portfolio of biocatalysis with special relevance for the synthesis and late-stage functionalization of APIs, in order to bypass pure chemical processes.

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4

Increasing evidence has shown that the metabolism and clearance of molecular targeted agents, such as sorafenib, plays an important role in mediating the resistance of HCC cells to these agents. Metabolism of sorafenib is performed by oxidative metabolism, which is initially mediated by CYP3A4. Thus, targeting CYP3A4 is a promising approach to enhance the sensitivity of HCC cells to chemotherapeutic agents. In the present work, we examined the association between CYP3A4 and the prognosis of HCC patients receiving sorafenib. Using the online tool miRDB, we predicted that has-microRNA-4277 (miR-4277), an online miRNA targets the 3’UTR of the transcript of cyp3a4. Furthermore, overexpression of miR-4277 in HCC cells repressed the expression of CYP3A4 and reduced the elimination of sorafenib in HCC cells. Moreover, miR-4277 enhanced the sensitivity of HCC cells to sorafenib in vitro and in vivo. Therefore, our results not only expand our understanding of CYP3A4 regulation in HCC, but also provide evidence for the use of miR-4277 as a potential therapeutic in advanced HCC.